Literature DB >> 25929570

Photoimmunotherapy of hepatocellular carcinoma-targeting Glypican-3 combined with nanosized albumin-bound paclitaxel.

Hirofumi Hanaoka1, Takahito Nakajima, Kazuhide Sato, Rira Watanabe, Yen Phung, Wei Gao, Toshiko Harada, Insook Kim, Chang H Paik, Peter L Choyke, Mitchell Ho, Hisataka Kobayashi.   

Abstract

AIM: Effectiveness of Glypican-3 (GPC3)-targeted photoimmunotherapy (PIT) combined with the nanoparticle albumin-bound paclitaxel (nab-paclitaxel) for hepatocellular carcinoma was evaluated. MATERIALS &
METHODS: GPC3 expressing A431/G1 cells were incubated with a phthalocyanine-derivative, IRDye700DX (IR700), conjugated to an anti-GPC3 antibody, IR700-YP7 and exposed to near-infrared light. Therapeutic experiments combining GPC3-targeted PIT with nab-paclitaxel were performed in A431/G1 tumor-bearing mice.
RESULTS: IR700-YP7 bound to A431/G1 cells and induced rapid target-specific necrotic cell death by near-infrared light exposure in vitro. IR700-YP7 accumulated in A431/G1 tumors. Tumor growth was inhibited by PIT compared with nontreated control. Additionally, PIT dramatically increased nab-paclitaxel delivery and enhanced the therapeutic effect.
CONCLUSION: PIT targeting GPC3 combined with nab-paclitaxel is a promising method for treating hepatocellular carcinoma.

Entities:  

Keywords:  Glypican-3; hepatoma; monoclonal antibody; nab-paxlitaxel; nanodelivery; photocyanine dye; photoimmunotherapy

Mesh:

Substances:

Year:  2015        PMID: 25929570      PMCID: PMC4420156          DOI: 10.2217/nnm.14.194

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  18 in total

1.  Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders.

Authors:  Z W Zhu; H Friess; L Wang; M Abou-Shady; A Zimmermann; A D Lander; M Korc; J Kleeff; M W Büchler
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 2.  Molecularly targeted therapy in hepatocellular carcinoma.

Authors:  Hung Huynh
Journal:  Biochem Pharmacol       Date:  2010-04-04       Impact factor: 5.858

Review 3.  Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma.

Authors:  Jorge Filmus; Mariana Capurro
Journal:  Mol Diagn       Date:  2004

Review 4.  Glypican-3: a new target for cancer immunotherapy.

Authors:  Mitchell Ho; Heungnam Kim
Journal:  Eur J Cancer       Date:  2010-11-26       Impact factor: 9.162

5.  Near infrared fluorescence-guided real-time endoscopic detection of peritoneal ovarian cancer nodules using intravenously injected indocyanine green.

Authors:  Nobuyuki Kosaka; Makoto Mitsunaga; Michelle R Longmire; Peter L Choyke; Hisataka Kobayashi
Journal:  Int J Cancer       Date:  2011-06-18       Impact factor: 7.396

Review 6.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Andrew Burroughs; Jordi Bruix
Journal:  Lancet       Date:  2003-12-06       Impact factor: 79.321

7.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.

Authors:  Mariana Capurro; Ian R Wanless; Morris Sherman; Gerrit Deboer; Wen Shi; Eiji Miyoshi; Jorge Filmus
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

8.  Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387 tissue samples.

Authors:  Daniel Baumhoer; Luigi Tornillo; Sylvia Stadlmann; Massimo Roncalli; Eva Karamitopoulou Diamantis; Luigi M Terracciano
Journal:  Am J Clin Pathol       Date:  2008-06       Impact factor: 2.493

Review 9.  Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?

Authors:  Richard S Finn
Journal:  Clin Cancer Res       Date:  2010-01-12       Impact factor: 12.531

Review 10.  Systemic therapy of hepatocellular carcinoma: are we making progress?

Authors:  Patricia Roxburgh; T R Jeffry Evans
Journal:  Adv Ther       Date:  2008-11       Impact factor: 3.845

View more
  17 in total

Review 1.  The Role of Glypicans in Cancer Progression and Therapy.

Authors:  Nan Li; Madeline R Spetz; Mitchell Ho
Journal:  J Histochem Cytochem       Date:  2020-07-06       Impact factor: 2.479

2.  Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody.

Authors:  Tadanobu Nagaya; Yuko Nakamura; Shuhei Okuyama; Fusa Ogata; Yasuhiro Maruoka; Peter L Choyke; Hisataka Kobayashi
Journal:  Mol Cancer Res       Date:  2017-06-06       Impact factor: 5.852

3.  Real-time monitoring of microdistribution of antibody-photon absorber conjugates during photoimmunotherapy in vivo.

Authors:  Qinggong Tang; Tadanobu Nagaya; Yi Liu; Jonathan Lin; Kazuhide Sato; Hisataka Kobayashi; Yu Chen
Journal:  J Control Release       Date:  2017-06-08       Impact factor: 9.776

Review 4.  Glypicans as Cancer Therapeutic Targets.

Authors:  Nan Li; Wei Gao; Yi-Fan Zhang; Mitchell Ho
Journal:  Trends Cancer       Date:  2018-09-28

Review 5.  Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?

Authors:  Yuko Nakamura; Ai Mochida; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2016-09-02       Impact factor: 4.774

Review 6.  Application of photodynamic therapy for liver malignancies.

Authors:  Heng Zou; Fusheng Wang; Jiang-Jiao Zhou; Xi Liu; Qing He; Cong Wang; Yan-Wen Zheng; Yu Wen; Li Xiong
Journal:  J Gastrointest Oncol       Date:  2020-04

Review 7.  Super enhanced permeability and retention (SUPR) effects in tumors following near infrared photoimmunotherapy.

Authors:  Hisataka Kobayashi; Peter L Choyke
Journal:  Nanoscale       Date:  2015-10-07       Impact factor: 7.790

8.  Near-infrared photoimmunotherapy of cancer: a new approach that kills cancer cells and enhances anti-cancer host immunity.

Authors:  Hisataka Kobayashi; Aki Furusawa; Adrian Rosenberg; Peter L Choyke
Journal:  Int Immunol       Date:  2021-01-01       Impact factor: 4.823

9.  Near-infrared photoimmunotherapy: a comparison of light dosing schedules.

Authors:  Fusa Ogata; Tadanobu Nagaya; Yuko Nakamura; Kazuhide Sato; Shuhei Okuyama; Yasuhiro Maruoka; Peter L Choyke; Hisataka Kobayashi
Journal:  Oncotarget       Date:  2017-05-23

10.  Comparative effectiveness of light emitting diodes (LEDs) and Lasers in near infrared photoimmunotherapy.

Authors:  Kazuhide Sato; Rira Watanabe; Hirofumi Hanaoka; Takahito Nakajima; Peter L Choyke; Hisataka Kobayashi
Journal:  Oncotarget       Date:  2016-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.